2022
Association of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer
Udelsman BV, Chang DC, Boffa DJ, Gaissert HA. Association of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2022, 115: 166-173. PMID: 35752354, DOI: 10.1016/j.athoracsur.2022.05.051.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerHigh-volume centersThoracic Surgeons General Thoracic Surgery DatabaseGeneral Thoracic Surgery DatabaseMedium-volume centersLow-volume centersCell lung cancerThoracic Surgery DatabaseNodal harvestParticipant centersLymph nodesLung cancerSurgery DatabaseLymph node samplingMultivariable logistic regressionHigher center volumeLong-term survivalPotential quality metricElective lobectomyAdjuvant therapyNodal yieldGuideline adherencePrimary outcomeUnivariable analysisMultivariable analysis
2017
The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension.
Kim C, Salazar M, Hoag J, Rosen J, Arnold B, Boffa D, Blasberg J. The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension. Journal Of Clinical Oncology 2017, 35: e20033-e20033. DOI: 10.1200/jco.2017.35.15_suppl.e20033.Peer-Reviewed Original ResearchTumor sizeAdjuvant chemoradiationAdjuvant chemotherapyAdjuvant therapyOverall cohortInferior survivalCurrent staging guidelinesNational Cancer DatabaseImportant prognostic variablesSubset of patientsPathologic N stageLarger tumor sizeNon-small cellProportional hazards modelN0 patientsN2 patientsNeoadjuvant therapyNodal diseaseImproved survivalPositive marginsStaging guidelinesCancer DatabaseN stagePrognostic variablesHazards model
2016
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2016, 103: 75-81. PMID: 28024700, DOI: 10.1016/j.lungcan.2016.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDatabases, FactualFemaleGuidelines as TopicHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePneumonectomyPostoperative PeriodRadiotherapySmall Cell Lung CarcinomaSurvival AnalysisConceptsStage I small cell lung cancerClinical stage ISmall cell lung cancerCell lung cancerAdjuvant chemotherapySurgical resectionPathologic upstagingStage IRadiation therapyNodal diseaseLung cancerPositive lymph node involvementNational Cancer DatabaseOutcomes of patientsLymph node involvementProportion of patientsCurative intentNodal upstagingSCLC patientsUpstaged patientsAdjuvant therapyNode involvementIndependent predictorsInferior survivalT descriptorRole of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumors